Organic Pressurized Fluid Patents (Class 424/45)
  • Patent number: 11905251
    Abstract: A compound 1-cyclopropyl-6-fluoro-7-(4-(2-hydroxy-3-(naphthalen-2-yloxy)propylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, its synthesis, and its use as an insecticidal agent.
    Type: Grant
    Filed: August 29, 2023
    Date of Patent: February 20, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Mohamed A. Gad
  • Patent number: 11883467
    Abstract: An insulin formulation and a method of preparing and using same. The insulin preparation includes insulin, oligosaccharide and sodium chloride at a ratio of 1:A:B (w:w:w respectively) with ranges of A and B are 1000-5000 and 10-50, respectively.
    Type: Grant
    Filed: September 6, 2022
    Date of Patent: January 30, 2024
    Assignee: Elgan Pharma Ltd
    Inventors: Michal Olshansky, Elena Ostrovsky, Stav Zeldis
  • Patent number: 11857545
    Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: January 2, 2024
    Assignee: Techfields Pharma Co., Ltd.
    Inventors: Chongxi Yu, Lina Xu
  • Patent number: 11779716
    Abstract: Methods of making components for a medicinal delivery device are described, in which a base composition comprising a polysulphone is applied to the surface of a component to create a base layer, a primer composition comprising a silane having two or more reactive silane groups separated by an organic linker group is applied to the base layer to create primed surface, and a coating composition comprising an at least partially fluorinated compound is applied to the primed surface. Corresponding coated components and a medicinal delivery device are disclosed.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: October 10, 2023
    Assignee: Kindeva Drug Delivery L.P.
    Inventors: Philip A. Jinks, Frans A. Audenaert
  • Patent number: 11744872
    Abstract: The invention relates to cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection. In particular, the invention provides a cyclosporine liquid formulation for use as an aerosol for inhalation in a method of preventing or treating pulmonary chronic graft rejection in single lung transplanted patients. The formulation is preferably administered once or twice daily. The formulation may be aerosolized with a nebulizer that comprises features for monitoring the time, date and duration of inhalation by the patient, in order to monitor patient adherence. The formulation according to the invention may be combined with standard immunosuppressants and corticosteroids.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: September 5, 2023
    Assignee: BREATH THERAPEUTICS GMBH
    Inventors: Martin Knoch, Oliver Denk
  • Patent number: 11730709
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: August 22, 2023
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew
  • Patent number: 11718785
    Abstract: Foaming fluid composition and methods for enhanced oil recovery are provided with enhanced foaming properties. The foaming composition may include a surfactant and Allium sativum oil where Allium sativum oil may be included in an amount ranging from 20 to 75 vol % in respect to the total volume of the surfactant and the Allium sativum oil. Methods of enhancing recovery of oil from an oil containing formation are also provided. Methods may include injecting a foaming composition into the oil containing formation, where the foaming composition may include a surfactant and Allium sativum oil. Methods may also include the foaming composition that includes Allium sativum oil in an amount ranging from 20 to 75 vol % in respect to the total volume of the surfactant and the Allium sativum oil.
    Type: Grant
    Filed: February 16, 2022
    Date of Patent: August 8, 2023
    Assignee: SAUDI ARABIAN OIL COMPANY
    Inventors: Deena Tayyib, Zuhair AlYousif, Abdulaziz AlQasim
  • Patent number: 11690937
    Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: July 4, 2023
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • Patent number: 11684628
    Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein (DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”) that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; psoriasis; ocular discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms) in post-menopausal women; post-operative hypothermia; post-anaesthetic shivering; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.
    Type: Grant
    Filed: September 11, 2021
    Date of Patent: June 27, 2023
    Assignee: IVIEW Therapeutics, Inc.
    Inventor: Edward T. Wei
  • Patent number: 11660416
    Abstract: Described are methods of administering therapeutic gases comprising high concentrations of nitric oxide, particularly concentrations above 2,000 ppm. The therapeutic gas may be administered at a certain dosing rate, such as less than 166 micrograms of nitric oxide per second. Also described are methods of administering a therapeutic gas comprising nitric oxide to a patient, wherein a dose of nitric oxide is administered from a portable device that includes a delivery system and a mini-cylinder. Methods of intermittent administration of nitric oxide pulses are also described.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: May 30, 2023
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Brahm Goldstein, Douglas Stuart Greene
  • Patent number: 11622920
    Abstract: The present invention belongs to the area of cosmetics, especially to a delivery system for actives to the skin, such as face masks and facial masks. Particularly, the present invention refers to a delivery system consisting of a basic body comprises nonwoven fibrous materials and an active-substance preparation which is an o/w emulsion or w/o emulsion, and a wetting liquid that comprises one or more actives to activate the delivery system.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: April 11, 2023
    Assignee: Symrise AG
    Inventors: Gerhard Schmaus, Sabine Lange, Ann Christin Weseloh, Dominik Stuhlmann
  • Patent number: 11612613
    Abstract: A pharmaceutically acceptable composition comprising trehalose and a pharmaceutically acceptable excipient and methods of delivering autophagy stimulating trehalose to a patient in need thereof.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: March 28, 2023
    Inventor: Robert Petcavich
  • Patent number: 11607410
    Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: March 21, 2023
    Assignee: MannKind Corporation
    Inventors: Marshall L. Grant, Grayson W. Stowell, Paul Menkin, John J. Freeman, Jr.
  • Patent number: 11571384
    Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: February 7, 2023
    Assignee: Hikma Pharmaceuticals USA Inc.
    Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
  • Patent number: 11559151
    Abstract: A washable pillow comprising of a molded foam core with antimicrobial resistance encased in a washable netting and a sleeve. The pillow may be washed and dried using conventional household methods without significant damage or loss of mechanical properties.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: January 24, 2023
    Assignee: TEMPUR WORLD, LLC
    Inventors: Sarah Russell, Stephen Wallace, Simon Simonsen, Anthony G. Turoso
  • Patent number: 11560375
    Abstract: Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: January 24, 2023
    Assignee: VeroScience LLC
    Inventor: Anthony H. Cincotta
  • Patent number: 11559505
    Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: January 24, 2023
    Assignee: Mexichem Fluor S.A. de C.V.
    Inventors: Stuart Corr, Timothy James Noakes
  • Patent number: 11559507
    Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: January 24, 2023
    Assignee: Mexichem Fluor S.A. de C.V.
    Inventors: Stuart Corr, Timothy James Noakes
  • Patent number: 11554160
    Abstract: Products, systems and methods are disclosed for lowering the concentrations of at least one of preservatives and fibrils in a liquid insulin composition. One method comprises replacing at least a portion of at least one of phenol and m-cresol with at least one of cyclodextrins, cyclodextrin polymers, cyclodextrin beads, and an ion exchange resin.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: January 17, 2023
    Assignee: Cell and Molecular Tissue Engineering, LLC
    Inventors: Ulrike W. Klueh, Donald L. Kreutzer
  • Patent number: 11547641
    Abstract: The invention relates to an anhydrous cosmetic or dermatological formulation comprising a viscose lipid-containing preparation and propellant gas consisting essentially of one or more substances selected from hydrofluorocarbons, n-butane, isobutane and propane. The formulation permits application to the skin by spraying of an otherwise nonsprayable preparation. The formulation is free from readily volatile solvents, surfactants, and preferably free from silicones.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: January 10, 2023
    Assignee: BEIERSDORF AG
    Inventors: Jonatan Scherer, David Winterstein, Heike Miertsch
  • Patent number: 11542226
    Abstract: This invention discloses cannabinoids linked with polyethylene glycol chains. The cannabinoid-polyethylene glycol chain molecules have one, two, or more cannabinoids linked with one, two, or more polyethylene glycol chains. Each cannabinoid-polyethylene glycol chain molecule may have one kind of cannabinoid or multiple kinds of cannabinoid. Methods to make these cannabinoid-polyethylene glycol linked chains are disclosed.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: January 3, 2023
    Assignee: Axim Biotechnologies, Inc.
    Inventors: Sergei Svarovsky, John W. Huemoeller, II
  • Patent number: 11517422
    Abstract: An intraocular lenses having a plurality of drug-containing microspheres attached to the intraocular lens. The intraocular lenses can be used for patients undergoing cataract surgery and reduces the need for recurrent surgery, follow-up treatment or postoperative eye-drops. Also provides a method for manufacturing such an intraocular lens and the use of an intraocular lens in the treatment of cataract.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: December 6, 2022
    Assignee: VISUSNANO LIMITED
    Inventors: Elodie Jane Siney, Joanna Mary Gould, Darren Pitt, Philip Alexander
  • Patent number: 11517525
    Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: December 6, 2022
    Assignee: Hikma Pharmaceuticals USA Inc.
    Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
  • Patent number: 11504310
    Abstract: The present invention relates to a stable and clear microemulsion comprising: an oil phase comprising an hydrophobic active ingredient; an aqueous phase; and a surfactant system comprising: a non-ionic primary surfactant system; a first non-ionic co-surfactant system, and a second non-ionic co-surfactant system.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: November 22, 2022
    Assignee: Firmenich SA
    Inventors: Wolfgang Fieber, Barbara Buchs
  • Patent number: 11504314
    Abstract: A multi-chrome cosmetic hair composition is disclosed. The composition includes a base formula suitable for hair and an interference pigment providing a colored background exhibiting interference colors that are observable at different angles of observation. The formula is sufficient to enable a homogenous suspension of the interference pigment. The formula includes a propellant, denatured alcohol, neutralized octylacrylamide/acrylates/butylaminoethyl methacrylate copolymer 4, a neutralizing agent sufficient to neutralize the octylacrylamide/acrylates/butylaminoethyl methacrylate copolymer 4 to a range of 80% to 100%, and a plasticizer. The interference pigment includes an opaque-type interference pigment consisting of particles ranging from 5 microns to 60 microns in size to fill in gaps on hair shaft surfaces and create a smooth, chrome-like effect on the hair.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: November 22, 2022
    Inventor: Hana Holecko
  • Patent number: 11471408
    Abstract: Provided herein are novel isotretinoin formulations that provide an enhanced targeted dermal delivery system for the drug isotretinoin with improved thermodynamic activity using no to a small level of ethanol relative to existing isotretinoin gel products, and methods for treatment of ichthyosis and other skin conditions using the same.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: October 18, 2022
    Assignee: TIMBER PHARMACEUTICALS LLC
    Inventors: Zachary Rome, Charles Rodney Greenaway Evans, Marc Barry Brown, Francesco Caserta
  • Patent number: 11464726
    Abstract: The invention relates to the non-therapeutic use of a composition comprising at least one 1,4:3,6 dianhydrohexitol for moisturising the skin, as well as to a preparation for topical use comprising at least one 1,4:3,6 dianhydrohexitol as a moisturising agent.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: October 11, 2022
    Assignee: ROQUETTE FRERES
    Inventors: Daniel Wils, Léon Mentink
  • Patent number: 11440936
    Abstract: This invention relates to methods of stimulating the activity of the human and animal enteric nervous system. The method comprises orally administering an aminoserol, such as squalamine, a naturally occurring aminosterol isolated from Squalus acanthias, or derivatives thereof, to a subject in need.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: September 13, 2022
    Assignee: Enterin, Inc.
    Inventor: Michael Zasloff
  • Patent number: 11426392
    Abstract: Compositions for treatment or prevention of viral infections, such as influenza A and B, coronaviruses, including but not limited to COVID-19 and any variant thereof, and rhinoviruses, along with related treatment methods. Certain compositions according to preferred embodiments may comprise chlorpheniramine and albuterol administered by inhalation in nebulized form.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: August 30, 2022
    Assignee: FERRER MEDICAL INNOVATIONS, LLC.
    Inventor: Gustavo Ferrer
  • Patent number: 11419769
    Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: August 23, 2022
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons
  • Patent number: 11395829
    Abstract: A compound having Formula I or its derivative may inhibit metallo-beta-lactamases. An investigation studying the effects of the compounds was provided by the invention of the activities of all subclasses (B1, B2, and B3) metallo-beta-lactamases. The compounds can be used for a pharmaceutical product with the ability to restore an anti-bacterial activity of a beta-lactam antibiotic, thereby treating and preventing a bacterial infection in an animal or human subject.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: July 26, 2022
    Assignee: MYONGJI UNIVERSITY INDUSTRY AND ACADEMIA COOPERATION FOUNDATION
    Inventors: Sang Hee Lee, Jung Hun Lee, Jeong Ho Jeon
  • Patent number: 11390437
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: July 19, 2022
    Assignee: GW Research Limited
    Inventor: Brian Anthony Whittle
  • Patent number: 11364261
    Abstract: A method for alleviating, preventing or treating symptoms of a viral infection such as common cold and flu, comprising administering to a subject in need thereof at least one solid form that releases molecular hydrogen upon exposure to the subject's gastric juice.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: June 21, 2022
    Assignee: H2 Universe, LLC
    Inventors: Vladimir L. Safonov, Marina Yu Safonov
  • Patent number: 11357782
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: June 14, 2022
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • Patent number: 11337923
    Abstract: Provided are a nanoliposome-microbubble conjugate in which a drug for hair loss treatment such as finasteride, minoxidil, dutasteride, etc. is encapsulated in a nanoliposome and a composition for alleviating or treating hair loss containing the same. Since an orally administered agent such as finasteride, currently useful as a drug for hair loss treatment, causes side effects, drug delivery through scalp application is most desirable, but the drug is not delivered to hair follicle cells through scalp application alone. Since a drug for hair loss treatment useful as an external preparation for skin causes various side effects, the concentration thereof that is used needs to be further lowered. The above nanoliposome-microbubble conjugate is capable of increasing the delivery efficiency of a drug for hair loss treatment at a low concentration, and is thus very effective at treating androgenic alopecia.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: May 24, 2022
    Assignee: MOOGENE MEDI CO., LTD.
    Inventor: Kyeong Nam Yu
  • Patent number: 11330816
    Abstract: The present invention relates to a composition for killing arthropods and their eggs, such as lice or ticks and nits. More in particular, the invention provides a composition for killing arthropods, said composition comprising at least 65% by weight of a mixture of saturated linear or branched hydrocarbons, wherein said hydrocarbons comprise a mixture of saturated linear or branched C10-C16 hydrocarbons and saturated linear or branched C17-C25 hydrocarbons, wherein the ratio of saturated linear or branched C10-C16 hydrocarbons to saturated linear or branched C17-C25 hydrocarbons by weight is lower than 15:85. The invention further relates to the use of such composition for killing arthropods and to a method for killing arthropods comprising the application of the present composition.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: May 17, 2022
    Assignee: Oystershell NV
    Inventor: Bart Rossel
  • Patent number: 11318112
    Abstract: A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: May 3, 2022
    Assignee: TASLY PHARMACEUTICAL GROUP CO., LTD.
    Inventors: He Sun, Xijun Yan, Naifeng Wu, Kaijing Yan, Yonghong Zhu, Shunnan Zhang, Xiaolin Bai, Xiaohui Ma, Yi He, Ting Li, Lei Li
  • Patent number: 11320383
    Abstract: The present invention relates to a method for the determination of the film forming amines on surfaces by the detection of a colored complex. The invention also relates to the use of the absorber material for the detection of the film forming amines. The invention also relates to a kit of parts comprising the components capable of the determination of film forming amines.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: May 3, 2022
    Assignee: KURITA WATER INDUSTRIES LTD.
    Inventors: Julia Jasper, Kirstin Zimmer, Andre De Bache, Wolfgang Hater
  • Patent number: 11311493
    Abstract: This invention relates to methods of preparing nanotherapeutic compounds and compositions comprising nanotherapeutic compounds. The nanotherapeutic compounds prepared according to the methods provided herein are useful for the treatment of disease, for example, cancer, in a subject in need thereof.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: April 26, 2022
    Assignee: MAA Laboratories, Inc.
    Inventor: Anjani Kumar Jha
  • Patent number: 11311502
    Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: April 26, 2022
    Assignee: MEXICHEM FLUOR S.A. DE C.V.
    Inventors: Stuart Corr, Timothy James Noakes
  • Patent number: 11304992
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: April 19, 2022
    Assignee: MANNKIND CORPORATION
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Patent number: 11291648
    Abstract: The present disclosure is directed to a composition comprising micronized cromolyn sodium, ?-lactose, and a salt of fatty acid, wherein the ?-lactose has a particle size distribution of D90 of 45-70 ?m, D50 of 10-35 ?m, and D10 of 2-13 ?m. The present disclosure is also directed to a method of treating Alzheimer's disease, amyloidosis-associated condition (AAC), traumatic brain injury, Huntington's disease, atherosclerosis, cytokine release syndrome (CRS), dementia, head injury, infection, neuroinflammation, prion disease, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, or asthma using the composition.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: April 5, 2022
    Assignees: The General Hospital Corporation, AZTherapies, Inc.
    Inventors: David R. Elmaleh, Juan B. Gonzalez
  • Patent number: 11260111
    Abstract: Disclosed are applications of a mussel adhesive protein or preparations thereof in suppression of skin inflammations. Specifically disclosed are applications of a mussel adhesive protein, preparations thereof and applications thereof in dermatitis, eczema, skin ulcer, technologies related to burns (comprising skin grafting), perniones, surgical incisions, herpes, abrasions, scars, psoriasis, erythema multiforme, skin damage after radiotherapy, skin cancers, folliculitis, urticaria and drug eruption, and applications in sunburn, polymorphous light eruption, pathological alopecia (comprising hair transplant), acne vulgaris, rosacea (that is, acne rosacea), and the like, and applications in the treatment of otitis externa.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: March 1, 2022
    Assignee: Jiangyin Bengt I. Samuelsson Institute of Life Science Co., Ltd.
    Inventors: Bengt Ingemar Samuelsson, Min Gao
  • Patent number: 11259521
    Abstract: Novel antimicrobial compositions and kits thereof containing these antimicrobial compositions, methods of manufacture and methods of use thereof are disclosed. The novel aqueous transdermal or topical delivery systems are useful, inter alia, for treatment of various microbial infections, including for use on tissue infections, particularly skin antisepsis and/or nasal mucosal tissue antisepsis to a mammalian host in need thereof.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: March 1, 2022
    Assignee: Infection Containment Company, LLC
    Inventors: Dennie W. Dyer, John A. Garruto
  • Patent number: 11246964
    Abstract: Systems and methods related to polymer foams are generally described. Some embodiments relate to compositions and methods for the preparation of polymer foams, and methods for using the polymer foams. The polymer foams can be applied to a body cavity and placed in contact with, for example, tissue, injured tissue, internal organs, etc. In some embodiments, the polymer foams can be formed within a body cavity (i.e., in situ foam formation). In addition, the foamed polymers may be capable of exerting a pressure on an internal surface of a body cavity and preventing or limiting movement of a bodily fluid (e.g., blood, etc.).
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: February 15, 2022
    Assignee: Arsenal Medical, Inc.
    Inventors: Upma Sharma, Irina Gitlin, Gregory T. Zugates, Adam Rago, Parisa Zamiri, Rany Busold, Robert J. Caulkins, Toby Freyman, Quynh Pham, Changcheng You, Jeffrey Carbeck
  • Patent number: 11246878
    Abstract: Composition and methods for treating infectious and inflammatory diseases using saccharide based products and therapies. Products can be implemented as a nutritional supplement, a food, a feed, a food additive, a feed additive, a therapeutic product, a rehydration salt, or a rehydration solution. The present disclosure relates generally to the fields of compositions and products containing the compositions, and the use of the compositions or the products for preventing and/or treating infectious or inflammatory diseases or conditions in particular gastrointestinal and respiratory diseases (diarrhea and influenza infections) or inflammatory.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 15, 2022
    Assignee: B&H BIOTECHNOLOGIES, LLC
    Inventor: Huiru Wang
  • Patent number: 11241371
    Abstract: A skin protecting product that includes cyclopentasiloxane, disiloxane, octylacrylamide, acrylates, butylaminoethyl methacrylate copolymer, isopropyl myristate, hydroxypropyl gluconomide, hydroxyproply ammonium gluconate, phenoxyethanol, Cetearyl alcohol, cetyl alcohol, cetyl PPG, PPG-10/1 dimethicone, hydroxyethyl urea, zinc oxide, titanium oxide, fragrance such as perfumes or colognes, vitamin C, and isodecyl neopentanoate. The skin protecting product is applied daily along with sunscreen to help reduce the chance of skin damage related conditions and illnesses that result from sun exposure. The product is applied on hard to reach areas such as the scalp. The product is weightless, so the user is not bothered by the application of the product. The skin protecting product comes in various forms such as a spray, gel or lotion.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: February 8, 2022
    Inventor: Janis Isabel Carreras
  • Patent number: 11225654
    Abstract: Provided are methods and compositions for self-cleaning that include a lysozyme capable of decomposing a microbe, a substrate applied to a solid surface, and a linker moiety bound to an outer surface of said substrate and an active group of said digestive protein, said linker moiety between said lysozyme and said substrate and covalently linking said lysozyme to a surface of said substrate optionally by an amide bond.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: January 18, 2022
    Assignees: TOYOTA MOTOR CORPORATION, THE UNIVERSITY OF AKRON
    Inventors: Ping Wang, Minjuan Zhang, Hongfei Jia, Archana H. Trivedi, Masahiko Ishii
  • Patent number: 11219589
    Abstract: The invention provides a method of strengthening the fibres of oxidatively-treated hair, the method comprising the sequential steps of: (i) washing the oxidatively-treated hair; (ii) soaking the washed hair in an aqueous treatment composition, and (iii) drying the soaked hair; characterised in that the aqueous treatment composition comprises at least 1% N-acetyl glycine (by weight based on the total weight of the composition).15 The invention also provides the use of an aqueous treatment composition comprising at least 1% N-acetyl glycine (by weight based on the total weight of the composition), for the enhanced strengthening of oxidatively-treated hair fibres relative to virgin hair fibres.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: January 11, 2022
    Assignee: CONOPCO, INC
    Inventor: Prem Kumar Cheyalazhagan Paul
  • Patent number: 11213500
    Abstract: A compounded transdermal cream for topical administration of a compounded therapy includes a nerve depressant such as gabapentin in an amount between approximately 5% and 15% by weight of the transdermal cream, an NSAID (Non-Steroidal Anti-Inflammatory Drug) such as nabumetone in an amount between approximately 5% and approximately 25% by weight of the transdermal cream, a tricyclic antidepressant such as amitriptyline in an amount between approximately 0.5% and approximately 4% by weight of the transdermal cream, a local anesthetic such as lidocaine and prilocaine in an amount between approximately 1% and approximately 7% by weight of the transdermal cream, and dimethyl sulfoxide (DMSO).
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: January 4, 2022
    Assignee: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II